Cartesian Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Cartesian Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2015 to Q3 2024.
  • Cartesian Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$17.6M, a 34.5% decline year-over-year.
  • Cartesian Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$53.5M, a 8.68% increase year-over-year.
  • Cartesian Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$86.4M, a 694% decline from 2022.
  • Cartesian Therapeutics, Inc. annual Operating Income (Loss) for 2022 was $14.5M.
  • Cartesian Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$4.6M, a 91.9% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$53.5M -$17.6M -$4.51M -34.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$49M $13.8M +$32.4M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$81.4M -$13.3M +$5.03M +27.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$86.4M -$36.3M -$27.8M -328% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$58.6M -$13.1M -$11.5M -717% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$47.1M -$18.6M -$32.5M -234% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$14.6M -$18.4M -$29.2M -271% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $14.5M -$8.5M -$12.6M -308% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 $27.1M -$1.6M +$370K +18.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $26.7M $13.9M +$13.4M +2966% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-17
Q1 2022 $13.3M $10.8M +$17.9M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$4.6M $4.08M +$12M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-07
Q3 2021 -$16.6M -$1.97M +$11.8M +85.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$28.3M $452K +$16.8M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$45.2M -$7.16M +$11.7M +62% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$56.8M -$7.9M +$4.67M +37.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-02
Q3 2020 -$61.5M -$13.7M -$1.94M -16.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$59.6M -$16.4M -$132K -0.81% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 -$59.4M -$18.8M -$6.97M -58.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q4 2019 -$52.5M -$12.6M +$1.93M +13.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-10
Q3 2019 -$54.4M -$11.8M +$4.15M +26% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$58.5M -$16.2M +$2.53M +13.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$61.1M -$11.9M +$3.96M +25% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$65M -$14.5M +$4.78M +24.8% Oct 1, 2018 Dec 31, 2018 10-K 2021-03-12
Q3 2018 -$69.8M -$15.9M -$2.09M -15.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$67.7M -$18.8M -$2.9M -18.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-08
Q1 2018 -$64.8M -$15.8M -$1.03M -6.98% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$63.8M -$19.3M -$5.42M -39.1% Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 -$58.4M -$13.9M -$6.39M -85.5% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$52M -$15.9M -$9.47M -148% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 -$42.5M -$14.8M -$7.84M -113% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 -$34.7M -$13.9M Oct 1, 2016 Dec 31, 2016 10-K 2019-03-15
Q3 2016 -$7.47M -$1.4M -23% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 -$6.4M -$85K -1.35% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 -$6.94M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q3 2015 -$6.07M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 -$6.32M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.